Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 5.15
FOLD's Cash to Debt is ranked lower than
64% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. FOLD: 5.15 )
Ranked among companies with meaningful Cash to Debt only.
FOLD' s Cash to Debt Range Over the Past 10 Years
Min: 5.15  Med: 35.04 Max: N/A
Current: 5.15
F-Score: 1
Z-Score: -0.17
M-Score: -3.32
WACC vs ROIC
9.45%
-225.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -51.54
FOLD's ROE (%) is ranked lower than
63% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. FOLD: -51.54 )
Ranked among companies with meaningful ROE (%) only.
FOLD' s ROE (%) Range Over the Past 10 Years
Min: -322.07  Med: -82.09 Max: -9.19
Current: -51.54
-322.07
-9.19
ROA (%) -24.45
FOLD's ROA (%) is ranked higher than
51% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. FOLD: -24.45 )
Ranked among companies with meaningful ROA (%) only.
FOLD' s ROA (%) Range Over the Past 10 Years
Min: -104.95  Med: -44.78 Max: -6.13
Current: -24.45
-104.95
-6.13
ROC (Joel Greenblatt) (%) -3385.52
FOLD's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. FOLD: -3385.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FOLD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2904.44  Med: -1385.29 Max: -134.99
Current: -3385.52
-2904.44
-134.99
Revenue Growth (3Y)(%) -100.00
FOLD's Revenue Growth (3Y)(%) is ranked lower than
98% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. FOLD: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
FOLD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -70.40 Max: -2.3
Current: -100
EBITDA Growth (3Y)(%) 2.00
FOLD's EBITDA Growth (3Y)(%) is ranked higher than
52% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. FOLD: 2.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
FOLD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -85.6  Med: -13.50 Max: 81.7
Current: 2
-85.6
81.7
EPS Growth (3Y)(%) 3.90
FOLD's EPS Growth (3Y)(%) is ranked higher than
60% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. FOLD: 3.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
FOLD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -85.2  Med: -14.20 Max: 54.6
Current: 3.9
-85.2
54.6
» FOLD's 10-Y Financials

Financials (Next Earnings Date: 2016-05-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

FOLD Guru Trades in Q1 2015

Steven Cohen 173,900 sh (New)
Jim Simons Sold Out
RS Investment Management 2,564,545 sh (-10.05%)
Louis Moore Bacon 140,641 sh (-37.49%)
Paul Tudor Jones 11,620 sh (-88.21%)
» More
Q2 2015

FOLD Guru Trades in Q2 2015

Chuck Royce 380,000 sh (New)
Paul Tudor Jones 106,356 sh (+815.28%)
Steven Cohen 916,700 sh (+427.14%)
Louis Moore Bacon 275,000 sh (+95.53%)
RS Investment Management 2,687,065 sh (+4.78%)
» More
Q3 2015

FOLD Guru Trades in Q3 2015

RS Investment Management 2,860,425 sh (+6.45%)
Steven Cohen Sold Out
Chuck Royce 334,000 sh (-12.11%)
Louis Moore Bacon 125,000 sh (-54.55%)
Paul Tudor Jones 38,735 sh (-63.58%)
» More
Q4 2015

FOLD Guru Trades in Q4 2015

RS Investment Management 3,488,863 sh (+21.97%)
Louis Moore Bacon 125,000 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 105,300 sh (-68.47%)
» More
» Details

Insider Trades

Latest Guru Trades with FOLD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.66
FOLD's P/B is ranked higher than
60% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. FOLD: 2.66 )
Ranked among companies with meaningful P/B only.
FOLD' s P/B Range Over the Past 10 Years
Min: 0.87  Med: 3.29 Max: 14.52
Current: 2.66
0.87
14.52
EV-to-EBIT -5.77
FOLD's EV-to-EBIT is ranked lower than
99.99% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. FOLD: -5.77 )
Ranked among companies with meaningful EV-to-EBIT only.
FOLD' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.3  Med: -2.30 Max: 2.2
Current: -5.77
-16.3
2.2
EV-to-EBITDA -5.85
FOLD's EV-to-EBITDA is ranked lower than
99.99% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. FOLD: -5.85 )
Ranked among companies with meaningful EV-to-EBITDA only.
FOLD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.6  Med: -2.60 Max: 4.1
Current: -5.85
-16.6
4.1
Current Ratio 2.94
FOLD's Current Ratio is ranked lower than
65% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. FOLD: 2.94 )
Ranked among companies with meaningful Current Ratio only.
FOLD' s Current Ratio Range Over the Past 10 Years
Min: 2.94  Med: 7.66 Max: 11.32
Current: 2.94
2.94
11.32
Quick Ratio 2.94
FOLD's Quick Ratio is ranked lower than
62% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. FOLD: 2.94 )
Ranked among companies with meaningful Quick Ratio only.
FOLD' s Quick Ratio Range Over the Past 10 Years
Min: 2.94  Med: 7.66 Max: 11.32
Current: 2.94
2.94
11.32

Valuation & Return

vs
industry
vs
history
Price/Graham Number 0.88
FOLD's Price/Graham Number is ranked higher than
78% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. FOLD: 0.88 )
Ranked among companies with meaningful Price/Graham Number only.
FOLD' s Price/Graham Number Range Over the Past 10 Years
Min: 1.14  Med: 1.14 Max: 1.14
Current: 0.88
Earnings Yield (Greenblatt) (%) -17.30
FOLD's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. FOLD: -17.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FOLD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 45.9  Med: 124.30 Max: 3397.3
Current: -17.3
45.9
3397.3

More Statistics

Revenue(Mil) $2
EPS $ -1.18
Beta1.03
Short Percentage of Float32.23%
52-Week Range $4.99 - 18.83
Shares Outstanding(Mil)125.21

Analyst Estimate

Dec16
Revenue(Mil)
EPS($) -0.76
EPS without NRI($) -0.76

Business Description

Industry: Biotechnology » Biotechnology
Compare:SZSE:300294, SHSE:600161, NAS:NKTR, SZSE:300009, HKSE:00570, ROCO:4174 » details
Traded in other countries:AM6.Germany,
Amicus Therapeutics Inc incorporated under the laws of the State of Delaware on February 4, 2002. The Company is a Biopharmaceutical Company focused on the discovery, development and commercialization of next-generation medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (LSDs). IT is focused on developing pharmacological chaperones as monotherapy agents (to be used without ERT) and its Chaperone-Advanced Replacement Therapy, or CHART platform of pharmacological chaperones in combination with ERT. Chaperone-Advanced Replacement Therapy, or CHART, platform has been used to develop our next-generation ERTs by co-formulating therapeutic enzymes with our proprietary pharmacological chaperones. It is also developing migalastat HCl as a monotherapy in two Phase 3 global registration studies ("Study 011" and "Study 012") for Fabry patients with genetic mutations that were amenable to this pharmacological chaperone in a cell-based assay. Study 011 is a 24-month study consisting of a 6-month double-blind, placebo-controlled treatment period (Stage 1); a 6-month open-label follow-up period (Stage 2); and a 12-month open-label extension phase. The Company currently operates in one business segment focusing on the development and commercialization of small molecule, orally administered therapies to treat a range of human genetic diseases. Its major competitors include pharmaceutical and biotechnology companies in the U.S. and abroad that have approved therapies or therapies in development for lysosomal storage disorders within our core programs. The Company owns certain trademarks in the U.S. and/or abroad, including A AMICUS THERAPEUTICS & design, AMICUS THERAPEUTICS and CHART.
» More Articles for FOLD

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Globus Medical Inc, Diplomat Pharmacy Inc, Zendesk Inc, and Amicus Thera Mar 28 2015 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 09 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 07 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 04 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
Amicus Therapeutics reports 1Q loss May 03 2016
Amicus Therapeutics reports 1Q loss May 03 2016
Amicus Therapeutics to Announce First Quarter 2016 Financial Results on May 3, 2016 May 03 2016
AMICUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 03 2016
Q1 2016 Amicus Therapeutics Inc Earnings Release - Before Market Open May 03 2016
Amicus Therapeutics Announces First Quarter 2016 Financial Results and Corporate Updates May 03 2016
Amicus Therapeutics to Announce First Quarter 2016 Financial Results on May 3, 2016 Apr 26 2016
Amicus Therapeutics to Announce First Quarter 2016 Financial Results on May 3, 2016 Apr 26 2016
Coverage initiated on Amicus Therapeutics by Robert W. Baird Apr 14 2016
Amicus Shares Barely Budge on Prediction of $3 Billion Buyout Apr 12 2016
Why Are Investors Excited About These 5 Stocks Today? Apr 12 2016
Why Valeant, Micron, and Three Other Stocks Are in Green Territory on Friday? Apr 01 2016
AMICUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 01 2016
Amicus (FOLD) Stock Soars After EU Regulator Recommended Drug Apr 01 2016
Amicus Therapeutics Receives Positive CHMP Opinion for Approval of Migalastat in Patients with Fabry... Apr 01 2016
Amicus Therapeutics Receives Positive CHMP Opinion for Approval of Migalastat in Patients with Fabry... Apr 01 2016
Amicus Shares Rise After Drug Recommended by EU Regulatory Panel Apr 01 2016
Amicus Fabry Drug Takes Big Step Toward European Approval Apr 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK